A hi-tech prostate cancer drug that offers hope to men who have run out of treatment options became available in the UK today.
Enzalutamide is licensed for patients with advanced prostate cancer who are no longer responding to hormone treatments or chemotherapy.
What to expect from the new drug:
- The new pill will cost around £2,500 a month.
- It can extend the lives of patients no longer being treated by almost five months.
- Seven out of 10 of the men in the Phase III Affirm trial taking enzalutamide were still alive after one year.
- It has a relative lack of side effects.
- The drug known as Xtandi, blocks molecular signals that allow the male hormone testosterone to fuel prostate cancer.
- It targets three different steps of the signalling pathway.
More top news
ITV News has obtained the first video from inside the Hatton Garden vault that was raided over the Easter Bank Holiday weekend.
London students are saying they will withhold their final rent until they get compensation over claims of cockroach and rodent infestation
Martin Stew speaks to this year's marathon competitors - including Paula Radcliffe - to discover the secret to surviving the weather.